ID: ALA75177

Max Phase: Preclinical

Molecular Formula: C16H15ClN4

Molecular Weight: 298.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  Clc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1

Standard InChI:  InChI=1S/C16H15ClN4/c17-10-4-3-5-11(8-10)20-15-14-12-6-1-2-7-13(12)21-16(14)19-9-18-15/h3-5,8-9H,1-2,6-7H2,(H2,18,19,20,21)

Standard InChI Key:  SVXFOLMQBCUDSL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 298.78

Molecular Weight (Monoisotopic): 298.0985

AlogP: 4.23

#Rotatable Bonds: 2

Polar Surface Area: 53.60

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.24

CX LogP: 4.37

CX LogD: 4.37

Aromatic Rings: 3

Heavy Atoms: 21

QED Weighted: 0.74

Np Likeness Score: -1.32

References

1. Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N..  (1996)  4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.,  39  (12): [PMID:8691423] [10.1021/jm960118j]

2. Shawky AM, Abourehab MAS, Abdalla AN, Gouda AM..  (2020)  Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency.,  185  [PMID:31655429] [10.1016/j.ejmech.2019.111780]

Source

Source(1):

• Scientific Literature